Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.

PloS One
Katsuhiro YoshikawaTomoharu Sugie

Abstract

CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73-10 assays), was also examined. CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73-10 assay did not show a correlation (p = 0.115). Using the 73-10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumo...Continue Reading

References

Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Oct 3, 2012·Journal of Cell Science·Yoshiyuki RikitakeYoshimi Takai
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Jun 18, 2017·Cancer Immunology, Immunotherapy : CII·Feng XuYuwen Zhu
Sep 6, 2017·Virus Research·Jonathan R BowersKatherine J D A Excoffon
Mar 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerJulie Brahmer
Jul 25, 2018·Apoptosis : an International Journal on Programmed Cell Death·Jian GaoChenghai Zhao
Oct 3, 2018·Cellular & Molecular Immunology·Paola Kučan BrlićStipan Jonjić
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Apr 30, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hongmei YongWei Zhao
Sep 29, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Nicola L LawsonCraig Barker
Dec 13, 2019·Clinical and Experimental Immunology·H Harjunpää, C Guillerey
Feb 6, 2020·International Journal of Molecular Sciences·Rosa MolfettaRossella Paolini

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.